J&J Nabs Omrix for $438M

This post was commissioned on November 24, 2008, and it was categorized as M&A.

Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.

Johnson & Johnson and Omrix Biopharmaceuticals, a biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced a definitive agreement whereby Omrix will be acquired for approximately $438 million in a cash tender offer. Omrix is expected to operate as a stand-alone entity reporting through ETHICON, a J&J company and leading provider of suture, mesh, hemostats and other products for a wide range of surgical procedures.

The acquisition of Omrix would strengthen its presence in active, biologic-based hemostats and convergent products for various surgical applications. ETHICON currently has exclusive distribution rights in the U.S. and the European Union for EVITHROM(TM) Thrombin Topical (Human) and EVICEL(TM) Fibrin Sealant (Human), two active, biologic-based hemostats manufactured by Omrix. ETHICON and Omrix are also partnering on a Fibrin Pad product candidate, currently in Phase II clinical trials, as an adjunct to control mild to moderate soft tissue bleeding.

Terms
———————–
- J&J to purchase all outstanding shares through a tender for $25/share

- 18% premium over last close and ~51% over last months average trading price

- $358M total net of estimated cash on hand

Assuming this transaction closes in 2008, Johnson & Johnson is expected to incur an estimated one-time, after-tax charge of approximately $120 million reflecting the write-off of in-process research and development charges (IPR&D). The acquisition is expected to be breakeven to slightly dilutive to Johnson & Johnson’s earnings per share in 2009.

Omrix has taken a big hit this year dropping from their 52 week high of 38.18 to a low of just 8.99 after a disappointing update regarding their phase 2 fibrin coagulant patch. I think JnJ got a pretty good bargain here.

(Via Marketwatch)

Theoretically Related Posts

September 10, 2008 -- ImClone Throws Down and Announces Additional Suitor (0)
March 12, 2009 -- CV Tells Astellas to Shove It: Looks to Gilead (0)
March 10, 2009 -- Mega-mergers Are Not Good For Business (0)
March 9, 2009 -- Merck to Buy Schering-Plough for $41.1 Billion Cash and Stock Deal (1)
January 30, 2009 -- Roche makes lowered, hostile offer for Genentech (AP) (0)
January 23, 2009 -- 5 Reasons Pfizer Shouldn’t Buy Wyeth and One Reason It Should (1)
October 30, 2008 -- GlaxoSmithKline to acquires Genelabs Technologies for $57M (0)
October 29, 2008 -- DFine Secures $30 Million in Series D Funding (0)
October 28, 2008 -- Lutonix Inc. Announces $20 Million Series B Financing (0)
October 23, 2008 -- No Rumors For You. Come Back. One Year (0)

This post was constructed by

Eben Tessari

.

Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.

If one were so inclined, one could follow him at any of these fine web 2.0 establishments: